Beatrix Bartok
Vice President - Clinical Development Biogen
Beatrix Bartok currently serves as the Vice President of Clinical Development at Vividion Therapeutics, Inc., a role held since November 2024. Prior to this position, Beatrix Bartok accumulated extensive experience at Gilead Sciences from January 2017 to November 2024, progressing through the ranks from Medical Director to Senior Medical Director and then to Executive Director. Earlier in Beatrix Bartok’s career, a role as Medical Advisor was held at Eli Lilly and Company from January 2015 to December 2016. Beatrix Bartok earned a degree from the University of Pécs, completing studies from 1991 to 1997.
Seminars
Thursday 23rd July 2026
Session Reserved
11:00 am
Wednesday 22nd July 2026
Panel Discussion: Positioning Novel Mechanisms in the Myasthenia Gravis Market to Deliver Differentiated Patient Benefit
9:30 am
- Comparing how FcRn inhibition, complement blockade, B-cell depletion and CAR-T differ mechanistically and where each may sit best based on disease biology
- Examining how mechanistic sequencing could address patients exposed to prior lines of therapy without clear biomarkerguidance
- Identifying emerging strategies for treating MG patients who fail FcRn inhibition, IgG degraders or complement therapies
- Gain insight into how to position assets in a saturated market while addressing inadequate responders and future curative ambition
